Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1159-1162

  Palumbo, R ^a,b   Palmeri, S ^c   Antimi, M ^d   Gatti, C ^e   Raffo, P ^a,b   Villani, G ^a,b   Toma, S ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

^e Division of Oncology   (Italy)

Author keywords

Continuous infusion; High dose chemotherapy; Ifosfamide; Soft tissue sarcomas

Indexed keywords

ANTHRACYCLINE DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; METASTASIS; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

EID: 0030726408     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008279426654     Document Type: Article

References (18)

1. Toma S, Palumbo R, Sogno G et al. Doxorubicin (or epidoxorubicin) combined with ifosasfamide in the treatment of adult soft tissue sarcomas. Ann Oncol 1993; 3: 119-23.
2. Santoro A, Tursz T. Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft-tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-45.
3. Frei E III, Antman K, Teicher B et al. Bone marrow autotrans-plantation for solid tumors-prospects. J Clin Oncol 1989; 7: 515-26.
4. Wiltshaw E, Westbury G, Harmer C et al. Ifosfamide plus mesna with and without Adriamycin in soft tissue sarcomas. Cancer Chemother Pharmacol 1986; 18: S10-2.
5. Antman KH, Ryan L, Elias A et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcomas. J Clin Oncol 1989; 7: 126-31.
6. Benjamin RS, Legha SS, Patel SR et al. Single-agent ifosfamide studies in sarcomas of soft-tissue and bone: The M.D. Anderson experience. Cancer Chemother Pharmacol 1993; 31: S174-9.
7. Schutte J, Kellner S, Seeber S. Ifosfamide in the treatment of softtissue sarcomas: Experience at the West German Tumor Center, Essen. Cancer Chemother Pharmacol 1993; 31: S194-8.
8. Bramwell V, Mouridsen H, Santoro A et al. Cyclophosphamide vs. ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987; 23: 311-21.
9. Elias AD, Eder JP, Skea T et al. High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990; 8: 170-8.
10. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-8.
11. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
12. Toma S, Palumbo R, Comandone A et al. Ambulatory 4-day continuous infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumors: A phase I study. Ann Oncol 1995; 6: 193-6.
13. Palumbo R, Toma S. Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: A phase I study. Eur J Cancer 1995: 31A (9): 1552-3 (Letter).
14. Miller AB, Hoogstraten B, Stazuet M et al. Reporting results of cancer teatments. Cancer 1981; 47: 210-4.
15. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
16. Pastorino V, Valente M, Santoro A et al. Results of salvage surgery from metastatic sarcomas. Ann Oncol 1990; 1: 269-73.
17. Casson AG, Putnam JB, Natarjian G et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcomas. Cancer 1992; 69: 662-9.
18. Choong PFM, Pritchard DJ. Rock MG et al. Survival after pulmonary metastasectomy in soft tissue sarcomas: Prognostic factors in 214 patients. Acta Orthop Scand 1995; 66: 561-8.